Autopsy and Case Reports
https://autopsyandcasereports.org/article/doi/10.4322/acr.2015.014
Autopsy and Case Reports
Article / Autopsy Case Report

Membranous nephropathy PLA2R+ associated with Chagas disease

José Cândido Caldeira Xavier-Júnior; Vanessa dos Santos Silva; Rosa Marlene Viero

Downloads: 7
Views: 363

Abstract

Chagas disease (CD) — a tropical parasitic disease caused by the protozoan Trypanosoma cruzi — is a major health problem in Latin America. The immune response against the parasite is responsible for chronic CD lesions. Currently, there are no reports of an association between CD and membranous nephropathy (MN). The detection of the phospholipase A2 receptor (PLA2R) as a target antigen in idiopathic MN can improve the differential diagnosis of primary and secondary forms of MN. The authors report the case of a male patient with positive serology for CD who presented sudden death and underwent autopsy. Histological sections of the heart showed multifocal inflammatory infiltrate composed mainly of mononuclear cells, leading to myocardiocytes necrosis and interstitial fibrosis. The kidneys showed a MN with positive expression for PLA2R. As far as we know, this is the first report of a case of primary MN in a patient with CD, with severe chronic cardiomyopathy and heart failure.
 

Keywords

Chagas Disease, Glomerulonephritis, Membranous, Receptors, Phospholipase A2

References

Coura JR, Borges-Pereira J. Chagas disease: 100 years after its discovery. A systemic review. Acta Trop. 2010;115(1-2):5-13. [https://doi.org/10.1016/j.actatropica.2010.03.008]. [PMID:20382097]

Fabbro DL, Olivera V, Bizai ML, et al. Humoral immune response against P2β from Trypanosoma cruzi in persons with chronic Chagas disease: its relationship with treatment against parasites and myocardial damage. Am J Trop Med Hyg. 2011;84(4):575-80. [https://doi.org/10.4269/ajtmh.2011.10-0261]. [PMID:21460013]

Costa RS, Monteiro RC, Lehuen A, Joskowicz M, Noël LH, Droz D. Immune complex-mediated glomerulopathy in experimental Chagas’ disease. Clin Immunol Immunopathol. 1991;58(1):102-14. [https://doi.org/10.1016/0090-1229(91)90152-Z]. [PMID:1824567]

Leon JS, Engman DM. Autoimmunity in Chagas heart disease. Int J Parasitol. 2001;31(5-6):555-61. [https://doi.org/10.1016/S0020-7519(01)00163-1]. [PMID:11334942]

Andrade ZA, de Queiroz AC. Lesões renais na esquistossomose hepatesplênica. Rev Inst Med Trop Sao Paulo. 1968;10(1):36-40. [PMID:5683035]

Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11-21. [https://doi.org/10.1056/NEJMoa0810457]. [PMID:19571279]

Debiec H, Martin L, Jouanneau C, et al. Autoantibodies specific for the phospholipase A2 receptor in recurrent and De Novo membranous nephropathy. Am J Transplant. 2011;11(10):2144-52. [https://doi.org/10.1111/j.1600-6143.2011.03643.x]. [PMID:21827616]

Debiec H, Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med. 2011;364(7):689-90. [https://doi.org/10.1056/NEJMc1011678]. [PMID:21323563]

Ronco P, Debiec H. Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy. J Am Soc Nephrol. 2010;21(4):564-9. [https://doi.org/10.1681/ASN.2009121220]. [PMID:20185638]

Zvaritch E, Lambeau G, Lazdunski M. Endocytic properties of the M-type 180-kDa receptor for secretory phospholipases A2. J Biol Chem. 1996;271(1):250-7. [https://doi.org/10.1074/jbc.271.1.250]. [PMID:8550569]

Glassock RJ. The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. Am J Kidney Dis. 2010;56(1):157-67. [https://doi.org/10.1053/j.ajkd.2010.01.008]. [PMID:20378220]

Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11-21. [https://doi.org/10.1056/NEJMoa0810457]. [PMID:19571279]

Qin W, Beck LH Jr, Zeng C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. 2011;22(6):1137-43. [https://doi.org/10.1681/ASN.2010090967]. [PMID:21566055]

Hoxha E, Harendza S, Zahner G, et al. An immunofluorescence test for phospholipase-A₂-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant. 2011;26(8):2526-32. [https://doi.org/10.1093/ndt/gfr247]. [PMID:21633097]

Hofstra JM, Beck LH Jr, Beck DM, Wetzels JF, Salant DJ. Anti-phospholipase A₂ receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2011;6(6):1286-91. [https://doi.org/10.2215/CJN.07210810]. [PMID:21474589]

Hoxha E, Kneißler U, Stege G, et al. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int. 2012;82(7):797-804. [https://doi.org/10.1038/ki.2012.209]. [PMID:22673885]

Segarra-Medrano A, Jatem-Escalante E, Carnicer-Cáceres C, et al. Evolution of antibody titre against the M-type phospholipase A2 receptor and clinical response in idiopathic membranous nephropathy patients treated with tacrolimus. Nefrologia. 2014;34(4):491-7. [PMID:25036063]

Ardalan M, Ghafari A, Hamzavi F, et al. Anti-phospholipase A2 receptor antibody in idiopathic membranous nephropathy: A report from Iranian population. J Nephropathol. 2013;2(4):241-8. [PMID:24475456]

Oh YJ, Yang SH, Kim DK, Kang S-W, Kim YS. Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy. PLoS One. 2013;8(4):e62151. [https://doi.org/10.1371/journal.pone.0062151]. [PMID:23637987]

Behnert A, Schiffer M, Müller-Deile J, Beck LH Jr, Mahler M, Fritzler MJ. Antiphospholipase A₂ receptor autoantibodies: a comparison of three different immunoassays for the diagnosis of idiopathic membranous nephropathy. J Immunol Res. 2014;2014(143274):1-5. [https://doi.org/10.1155/2014/143274]. [PMID:24812637]

Segarra-Medrano A, Jatem-Escalante E, Quiles-Pérez MT, et al. Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy. Nefrologia. 2014b;34(3):353-9. [PMID:24798555]

Noel LH, Zanetti M, Droz D, Barbanel C. Long-term prognosis of idiopathic membranous glomerulonephritis. Study of 116 untreated patients. Am J Med. 1979;66(1):82-90. [https://doi.org/10.1016/0002-9343(79)90486-8]. [PMID:420255]

Donadio JV Jr, Torres VE, Velosa JA, et al. Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int. 1988;33(3):708-15. [https://doi.org/10.1038/ki.1988.56]. [PMID:3367560]

Viero R, Soares V. Nefropatia membranosa: estudo clínico-morfológico de 28 pacientes. J Bras Nefrol. 2002;24(4):161-7.

Polanco N, Gutiérrez E, Rivera F, et al. Spontaneous remission of nephrotic syndrome in membranous nephropathy with chronic renal impairment. Nephrol Dial Transplant. 2012;27(1):231-4. [https://doi.org/10.1093/ndt/gfr285]. [PMID:21624942]

Svobodova B, Honsova E, Ronco P, Tesar V, Debiec H. Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Nephrol Dial Transplant. 2013;28(7):1839-44. [https://doi.org/10.1093/ndt/gfs439]. [PMID:23223223]

Row PG, Cameron JS, Turner DR, et al. Membranous nephropathy. Long-term follow-up and association with neoplasia. Q J Med. 1975;44(174):207-39. [PMID:1178811]


 


Publication date:
01/13/2016

569634a05ce02a7962000000 autopsy Articles

Autops Case Rep

Share this page
Page Sections